For nearly two years, one of the biggest unanswered questions surrounding retatrutide wasn’t how much weight people would lose. We already had a pretty good idea of that from the Phase 2 data. The bigger question was what would happen once Lilly reached the FDA. Would retatrutide be reviewed as a traditional drug, or would it ultimately be regulated as …